SC 13D

Company

Aligos Therapeutics, Inc.

Filed

October 22, 2020

Accession Number

0001193125-20-274431

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →